Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NGM831||NGM-831|NGM 831||NGM831 is a humanized antibody that targets ILT3 and prevents the interaction of ILT3 with its ligands fibronectin and ApoE, potentially resulting in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr LB216).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05215574||Phase I||NGM831 NGM831 + Pembrolizumab||Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors||Recruiting||USA||0|